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An unexpected role for caspase-2 in neuroblastoma
L Dorstyn*,1,2, J Puccini1, A Nikolic1, S Shalini1, CH Wilson1, MD Norris3, M Haber3 and S Kumar*,1,2
Caspase-2 has been implicated in various cellular functions, including cell death by apoptosis, oxidative stress response,
maintenance of genomic stability and tumor suppression. The loss of the caspase-2 gene (Casp2) enhances oncogene-mediated
tumorigenesis induced by E1A/Ras in athymic nude mice, and also in the El-Myc lymphoma and MMTV/c-neu mammary tumor
mouse models. To further investigate the function of caspase-2 in oncogene-mediated tumorigenesis, we extended our studies
in the TH-MYCN transgenic mouse model of neuroblastoma. Surprisingly, we found that loss of caspase-2 delayed tumorigenesis
in the TH-MYCN neuroblastoma model. In addition, tumors from TH-MYCN/Casp2 / mice were predominantly thoracic
paraspinal tumors and were less vascularized compared with tumors from their TH-MYCN/Casp2þ /þ counterparts. We did not
detect any differences in the expression of neuroblastoma-associated genes in TH-MYCN/Casp2 / tumors, or in the activation of
Ras/MAPK signaling pathway that is involved in neuroblastoma progression. Analysis of expression array data from human
neuroblastoma samples showed a correlation between low caspase-2 levels and increased survival. However, caspase-2 levels
correlated with clinical outcome only in the subset of MYCN-non-amplified human neuroblastoma. These observations indicate
that caspase-2 is not a suppressor inMYCN-induced neuroblastoma and suggest a tissue and context-specific role for caspase-2
in tumorigenesis.
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The caspase family of cysteine proteases are highly con-
served regulators of cell death by apoptosis.1 In addition to
their pro-apoptotic function, many caspases also have non-
apoptotic roles in other physiological processes, such as
inflammation, necrosis and tumor suppression.2–4 The most
highly conserved caspase, caspase-2, has recently been
demonstrated to function in the cellular stress response,
protection against ageing, maintenance of genome stability
and in tumor suppression.2,5–8
The tumor suppressor function of caspase-2 was first
demonstrated using E1A/Ras-transformed caspase-2-defi-
cient mouse embryonic fibroblasts (MEFs), which showed an
increased tumorigenic potential in athymic nude mice.7
Further supporting evidence came from experiments demon-
strating that caspase-2 deficiency enhances B-cell lymphoma
development in Em-Myc transgenic mice7 and mammary
carcinomas inMMTV/c-neumice,9 suggesting that caspase-2
prevents oncogene-induced lymphomas and epithelial
tumors. Importantly, tumor suppression by caspase-2 is also
evident in the non-oncogene-drivenAtm / thymomamouse
model.10
Given its role in apoptosis, the tumor suppression
function of caspase-2 was thought to be associated with this
role, via the elimination of mutagenic or potentially tumori-
genic cells. Recent studies have now indicated that the role of
caspase-2 may extend beyond apoptosis and that its
tumor suppression function may, in part, be mediated by
maintaining genomic stability and/or the oxidative stress
response. Caspase-2-deficient MEFs and tumor cells from
Em-Myc/Casp2 / , MMTV/c-neu/Casp2 / and Atm /
;Casp2
 /
mice all display aberrant proliferation, and
increased genomic instability6,9,10 and indicate that cas-
pase-2 is important for the maintenance of genome stability.
Importantly, the role of caspase-2 in maintaining genomic
stability in primary cells appears to be required for its tumor
suppressor function.10
Genomic instability is a hallmark of cancer11 and the
overexpression of Myc family oncoproteins is commonly
associated with genomic instability and a wide spectrum of
human cancers.12–14 Interestingly, a common feature of the
oncogene-induced tumor models used in the study of
caspase-2 tumor suppressor function is the overexpression
of c-Myc15 or aberrant c-Myc signaling.16–18 Given the role of
Myc proteins as keymediators of genomic instability as well as
cell proliferation, cell growth and DNA damage, we were
interested in further assessing whether caspase-2 can
promote tumor suppression in other MYC-dependent mouse
tumor models. We used the MYCN mouse model of
neuroblastoma (TH-MYCN mouse), in which MYCN is
constitutively expressed under the control of the rat tyrosine
hydroxylase (TH) promoter leading to neural crest cell-specific
expression and early-onset neuroblastoma.19 Amplification of
MYCN occurs in B20% of human neuroblastomas and high
MYCN protein levels are strongly associated with tumor
progression and poor clinical outcome.20,21 Thus, the TH-
MYCN transgenic mouse model recapitulates many clinical
features of aggressive neuroblastomas in humans and
provides a powerful model of preclinical neuroblastoma.19,22
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MYCN-mediated neuroblastoma onset and progression is
commonly associated with additional genetic events, includ-
ing the expression of the key genes including Odc1, Mrp1,
SirT1 and Ras.23–25 A recent study has found that caspase-8
is in fact a potent suppressor of neuroblastoma, with the loss
of caspase-8 expression occurring in B70% of neuroblas-
toma patients.26,27 Interestingly, the loss of caspase-8 also
promotes bone marrow metastasis in the TH-MYCN neuro-
blastoma mouse model.26,27 The role of other caspases in
neuroblastoma has not previously been examined, and given
the function of caspase-2 in tumor suppression, provided
additional relevance in assessing its role in this model.
This study shows that caspase-2 is not able to suppress
neuroblastoma development in TH-MYCNmice. In contrast to
a role for caspase-2 as a tumor suppressor, our findings
demonstrate that loss of caspase-2 somewhat delays
neuroblastoma onset in mice. Interestingly, expression array
data from human neuroblastoma show a strong correlation
between low caspase-2 levels and improved outcome. Our
data demonstrate that the tumor suppressor function of
caspase-2 is not specific to Myc-mediated oncogenesis and
that its role is likely to be tissue- and/or context-specific.
Results
Caspase-2 deficiency delays neuroblastoma development
in TH-MYCN mice. Loss of caspase-2 leads to enhanced
tumorigenesis following c-Myc-mediated oncogenic stress7,9
but has a minimal role in regulating tumor development in
carcinogen- or irradiation-induced tumor models.28 To further
examine the tumor-suppressive role of caspase-2 following
MYC-mediated oncogenic stress in different tissues, we
used the TH-MYCN mouse model of neuroblastoma
to generate TH-MYCN transgenic/Caspase-2-deficient
(TH-MYCN/Casp2 / ) mice and monitored these mice for
tumor development over a 1-year period.
The TH-MYCN mice were originally derived in the SV129J
genetic background and, consistent with previous studies29 in
our specific pathogen-free animal house conditions, these
mice developed neuroblastoma at an average age of
6.65±0.694 weeks (mean±S.D.) and incidence of 100%
(n¼ 34; Figure 1a). Given that the Casp2 / mice were
derived on a C57BL6 genetic background and the genetic
background can affect tumor development,30 we generated
cohorts of TH-MYCN/Casp2þ /þ , TH-MYCN/Casp2þ / and
TH-MYCN/Casp2 / mice in a mixed genetic background
(Sv129J/C57BL6) and once they had achieved congenicity,
compared tumor onset in littermates. Consistent with previous
reports for TH-MYCN (C57BL6) mice, the TH-MYCN
(Sv129J/C57BL6) develop tumors at a later, and more
variable onset (average age 15.9±12.47 weeks) with
reduced incidence (28/33¼ 84.8%) compared with TH-MYCN
(Sv129J) mice (Figure 1a).
Intriguingly, in contrast to its expected role as a tumor
suppressor, the loss of caspase-2 delayed tumor onset in
TH-MYCN (Sv129J/C57BL6) mice, with only 14 out of 22
(63.63%) mice developing tumors at an average onset of
19.82±18.5 weeks compared with 14.09±13.5 weeks for
their TH-MYCN/Casp2þ /þ littermates (P¼ 0.0173 log-rank
test; Figure 1b and Supplementary Figures S1a and c).
In addition, loss of even a single caspase-2 allele significantly
delayed tumor onset in these mice (P¼ 0.0303; Figure 1b).
Furthermore, whereas the TH-MYCN/Casp2þ /þ mice
predominantly developed abdominal tumors arising from
the adrenal medulla, the majority of TH-MYCN/Casp2 /
mice developed smaller paraspinal thoracic tumors
(Supplementary Figure S1b). Further analysis of tumors
showed that there was no difference in relative tumor size
between genotypes and no correlation between tumor onset
and size (Supplementary Figure S1d). We carried out
histological examination to assess metastatic dissemination
of tumor cells to the lung, kidney and bone marrow as
previously reported in TH-MYCN mice;19,27,31 however, the
extent of metastasis was comparable between TH-MYCN/
Casp2þ /þ and TH-MYCN/Casp2 / mice (data not shown).
Histological examination of tumors from TH-MYCN/
Casp2þ /þ and TH-MYCN/Casp2 / mice was consistent
with the presence of islands of undifferentiated neuroblas-
toma cells sometimes surrounded by clusters of larger,
differentiated neuroblastoma cells and tangible body macro-
phages characteristic of mouse neuroblastoma31 (Figure 2).
The main histological difference between the two groups
of tumors was the observation that the majority of the
abdominal tumors from TH-MYCN/Casp2 / mice did not
appear vascularized (only 3/14 tumors exhibiting obvious
vasculature) compared with abdominal tumors from
Figure 1 Caspase-2 deficiency delays the onset of MYCN-mediated neuroblastoma. (a) Comparison of Kaplan–Meier survival curves of TH-MYCN mice (Sv129J mouse
background, n¼ 30) and TH-MYCN mice (C57Bl6/Sv129J mixed background; n¼ 31). P-value determined by log-rank (Mantel cox) test. (b) Survival curves of TH-MYCN/
Casp2þ /þ , TH-MYCN/Casp2þ / and TH-MYCN/Casp2 / mice (C57BL6/Sv129J mixed littermates). P-value for TH-MYCN/Casp2þ /þ compared with TH-MYCN/
Casp2 / mice was determined by log-rank test, with Po0.05 being significant
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TH-MYCN/Casp2þ /þ (25/38 were highly vascularized;
Figure 2). These data may indicate that caspase-2 deficiency
affects tumor progression.
Loss of caspase-2 does not affect cell proliferation or
apoptosis in MYCN neuroblastoma. Previous studies
have demonstrated a role for caspase-2 in the regulation of
cell proliferation and cell cycle progression.6,10 We therefore
assessed the proliferative capacity of TH-MYCN/Casp2 /
tumors, as determined by proliferating cell nuclear antigen
(PCNA) expression. There were no significant differences in
PCNA levels in abdominal neuroblastomas between geno-
types (Figure 3a). Interestingly, there was a trend toward
reduced PCNA expression in the paraspinal thoracic tumors
from TH-MYCN/Casp2 / mice; however, given the high
variability in some tumor samples, this difference was not
significant (P¼ 0.08, Figure 3a). These data demonstrate
that the loss of caspase-2 does not enhance the proliferative
capacity of TH-MYCN/Casp2 / tumors.
We next assessed the level of apoptosis in the MYCN
tumors using TUNEL (terminal deoxynucleotidyl transferase
dUTP nick end labeling) immunohistochemistry. There was
no significant difference in the percentage of TUNEL-
positive cells in TH-MYCN/Casp2 / tumors compared with
TH-MYCN/Casp2þ /þ tumors, indicating that caspase-2 does
not have a significant role in neuroblastoma cell death
(Figure 3b). Given that caspase-2 has been shown to have
a role in the DNA damage response, we isolated and cultured
Figure 2 Histopathology of TH-MYCN/Casp2 / neuroblastomas. Representative images ( 40) of hematoxylin and eosin stained (a) abdominal tumors and
(b) thoracic tumors, from TH-MYCN/Casp2þ /þ and TH-MYCN/Casp2 / mice. Three different tumor samples for each genotype are shown, with numbers indicating animal
number. Arrows highlight tangible body macrophages. Scale bar represents 50 mm
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primary neuroblastoma cells32 and exposed them to gamma
radiation. We did not observe any significant differences in
the level of apoptosis in TH-MYCN/Casp2 / compared with
TH-MYCN/Casp2þ /þ cells (data not shown).Wewere unable
to detect p53 or phosphorylated p53 (Ser15) by immunoblot-
ting, in any of the tumor samples analyzed, which is consistent
with neuroblastomas lacking p53 mutation, and consistent
with previous reports.33,34 Furthermore, we did not detect any
differences in p53 transcript levels in tumor samples or in the
levels of p53 target genes, Mdm2 and p21 (Supplementary
Figures S2a and b). These data indicate that DNA damage-
mediated cell death and p53 regulation in neuroblastomas is
caspase-2-independent.
Given caspase-2 has an important role in maintaining
genomic stability,6 we assessed the frequency of aneuploidy
in TH-MYCN/Casp2þ /þ and TH-MYCN/Casp2 / neuro-
blastoma cells. However, we did not detect any differences in
the extent of aneuploidy in TH-MYCN/Casp2 / tumor cells
(Supplementary Figure S3), indicating that caspase-2 does
not function to maintain genomic integrity in MYCN-expres-
sing neuroblastoma cells.
Neuroblastoma-associated gene expression in
TH-MYCN/Casp2 / tumors. Neuroblastoma is character-
ized at the molecular level by the high expression of several
genes, including the neuronal markers TH and S100A6.
In addition, several MYCN target genes, including multidrug
resistant protein-1 (Mrp1), sirtuin 1 (SirT1) and ornithine
decarboxylase (Odc1), are associated with the onset and
aggressiveness of disease.19,23–25 To determine whether the
reduced tumor incidence in TH-MYCN/Casp2 / mice was
associated with disrupted expression of these neuroblas-
toma-associated genes, we examined their transcript levels
in both thoracic and abdominal tumors (Figure 4). As
expected, MYCN transgene expression was similar in both
TH-MYCN/Casp2þ /þ and TH-MYCN/Casp2 / tumours
at both the transcript and protein levels (Figures 4 and 5),
indicating that altered MYCN expression was not responsible
for the reduced tumor incidence in the TH-MYCN/Casp2 /
mice. Whereas expression levels of the neuroblastoma-
related genes assessed were lower in thoracic tumors
compared with abdominal tumors, importantly, there
were no differences between TH-MYCN/Casp2þ /þ and
TH-MYCN/Casp2 / (Figure 4), indicating that the loss of
caspase-2 does not affect neuroblastoma progression in
mice.
Ras/MAPK pathway activation in caspase-2-deficient
MYCN neuroblastomas. Previous studies have demon-
strated that MYCN is tightly regulated at the transcript and
protein levels, by Ras signaling.24,35 We therefore assessed
whether there were any differences in Ras pathway signaling
and activation in caspase-2-deficient MYCN neuroblastoma,
in both thoracic and abdominal samples. Whereas some
caspase-2-deficient tumors exhibited increased Ras expres-
sion (1/5 abdominal and 2/5 thoracic tumors), this was not
significant and we did not detect any significant alterations in
activation of downstream pathway components, including
Erk1/2 phosphorylation or Akt phosphorylation (Figure 5).
Our data therefore indicate that the delayed onset of MYCN-
mediated neuroblastoma in caspase-2-deficient mice is not
due to altered Ras signaling.
Figure 3 Caspase-2 does not affect proliferation or cell death in neuroblastoma. Representative images ( 40) and quantification of (a) PCNA and (b) TUNEL
immunohistochemistry on formalin-fixed, paraffin-embedded neuroblastoma sections derived from TH-MYCN/Casp2þ /þ (n¼ 10 and 9, respectively) and TH-MYCN/
Casp2 / (n¼ 9 and 11, respectively) mice. Scale bar represents 50 mm
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Loss of caspase-2 is associated with increased survival
in human neuroblastoma. Our finding that caspase-2 does
not act as a tumor suppressor in MYCN-driven neuroblas-
toma was unexpected and further reinforced the notion that
its role in tumor suppression is context- and tissue-specific.
To confirm this finding we analyzed publicly available
expression array data sets obtained using primary human
neuroblastoma tumor samples. Surprisingly, high levels of
caspase-2 were strongly predictive of poor neuroblastoma
outcome in the overall cohort (Po0.0001; Figure 6a). We
analyzed data from MYCN-amplified and non-amplified
neuroblastomas separately, and whereas there was only a
small subset of MYCN-amplified tumor data available
(N¼ 16), there was no correlation between caspase-2 gene
expression and outcome in MYCN-amplified human neuro-
blastomas. Interestingly, there was a significant correlation
between low caspase-2 levels and increased survival in
MYCN non-amplified human neuroblastoma (Figure 6b).
These data are in contrast to the mouse TH-MYCN
neuroblastoma data presented here and may indicate that
the delayed tumorigenesis observed in caspase-2-deficient
TH-MYCN mice may be influenced by additional genetic
Figure 4 Expression of neuroblastoma-associated genes in TH-MYCN/Casp2 / tumors. qPCR analysis of MYCN, TH, S100A6, Odc1, Mrp, SirT1 gene expression in
TH-MYCN/Casp2þ /þ and TH-MYCN/Casp2 / tumors (n¼ 6 abdominal and n¼ 5 thoracic tumors per genotype). Expression of each gene was determined relative to
internal b-actin control gene. Data represent the mean±S.E.M.
Figure 5 Ras signaling in TH-MYCN/Casp2 / neuroblastoma. Western blots showing expression levels of MYCN and Ras pathway components; Ras, Erk1/2,
phospho-Erk1/2, Akt, phospho-Akt in (a) abdominal and (b) thoracic tumors from TH-MYCN/Casp2þ /þ and TH-MYCN/Casp2 / mice. Caspase-2 deficiency was validated
by western blotting with anti-Caspase-2 antibody. Samples were run on three separate blots, with b-actin shown as a loading control
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aberrations.36 These findings are the first report of a role for
caspase-2 in neuroblastoma and further emphasize the
context-specific role of caspase-2 in tumorigenesis.
Discussion
We previously provided the first direct evidence for a tumor
suppressor function for caspase-2 using the Em-Myc trans-
genic mouse model.7 Here we utilized TH-MYCN transgenic
mice as an alternative MYC-driven mouse tumor model to
further investigate the tumor suppressor function of caspase-
2 in different tissues. Unexpectedly, we show that deletion of
caspase-2 delays neuroblastoma development in the TH-
MYCN mouse model. Indicating that loss of caspase-2 may
have a somewhat protective function in MYCN-driven
neuroblastoma in mice. This conclusion is also supported by
Kaplan–Meier survival data showing that high, rather than low,
levels of caspase-2 in primary human neuroblastomas are
associated with poor outcome.
Caspase-2 strongly suppresses tumorigenesis in the
EmMyc B-cell lymphoma model. Given the regulation of
c-Myc and MYCN activation and signaling is similar, we
hypothesized that caspase-2 may also act as a suppressor of
MYCN-mediated tumorigenesis. The finding that caspase-2
does not suppress MYCN-mediated neuroblastoma may
indicate a tissue-specific function for caspase-2 and may also
provide us with important information on the differential role(s)
of caspase-2 in regulating c-Myc- and MYCN-mediated
tumorigenesis. There are several key differences between
c-Myc- and MYCN-mediated oncogenesis, including (i)
MYCN-induced neuroblastoma is primarily an embryonal
tumor; (ii) c-Myc and MYCN are differentially expressed
during development with MYCN predominantly expressed in
undifferentiated neuronal cells of neonatal mice and switched
off after birth;37 and (iii) c-Myc and MYCN are differentially
regulated at the protein level by Ras and SirT1.24,38–40
MYCN amplification and high MYCN protein levels occur in
25% of human neuroblastomas and are essentially associated
with poor prognosis in human neuroblastoma.41–44 MYCN-
mediated neuroblastoma onset and progression are strongly
associated with expression of the key genes including Odc1,
Mrp1, SirT1 and Ras.23–25 Studies using neuroblastoma cell
lines demonstrated that Ras regulates MYCN translation and
proteolysis,35,40 whereas Sirt1 promotes MYCN protein stabi-
lity and neuroblastoma progression.24,45,46 Whereas we
observed an increase in Ras protein levels in some caspase-
2-deficient MYCN tumors, we did not observe any significant
differences in MYCN protein levels, or activation of MAPK
pathway components. Therefore, the delay inMYCN-mediated
neuroblastoma, in caspase-2-deficient TH-MYCN mice, is
unlikely to be caused by altered Ras function. We did not
detect any differences in SirT1 mRNA or protein expression
and were unable to detect expression of acetylated p53
(an indicator of SirT1 activity) in any of the tumor tissues or
neuroblastoma cells from either genotypes; therefore, we
cannot rule out a role for SirT1 in the delayed tumorigenesis
observed in TH-MYCN/Casp2 / mice.
The absence of changes in molecular markers associated
with neuroblastoma onset and progression, in TH-MYCN/
Casp2 / tumors, may indicate that caspase-2 affects tumor
initiation rather than tumor progression. Further support for
this suggestion comes from the differences in the pattern of
tumor presentation observed in the caspase-2-deficient mice,
with TH-MYCN/Casp2 / tumors being less vascularized
and predominantly paraspinal thoracic tumors of the sympa-
thetic ganglia. Angiogenesis has an important role in the
progression of neuroblastoma, with tumor vascularity highly
correlated with an aggressive and advanced disease pheno-
type.47,48 Neuroblastoma is a common embryonal tumor
arising from neural crest cells of the sympathetic nervous
system and frequently develops in the adrenal medulla. Our
findings indicate that the loss of caspase-2 may act to hinder
development of adrenal medulla tumors. Together, our
Figure 6 Caspase-2 gene expression is correlated with poor survival in neuroblastoma patients. Event-free survival curves for neuroblastoma patients from publicly
available expression array data showing (a) total survival outcome independent of MYCN amplification (n¼ 88) and in (b) subsets of patients with MYCN amplification (n¼ 16)
and without MYCN amplification (n¼ 72), showing high caspase-2 expression correlation with poor survival outcome in MYCN non-amplified tumors. P-values using the
method of Kaplan–Meier are shown
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findings demonstrate that neuroblastoma development is
delayed in TH-MYCN/Casp2 / mice.
Whereas c-Myc and MYCN can partly compensate for one
another in knockout mice,49 their roles are not entirely
redundant and their role and regulation in tumorigenesis is
distinct.35,50 An importantmediator of c-Myc-induced genomic
instability and tumorigenesis is the ARF–Mdm2–p53 tumor
suppressor pathway, and many adult tumors with high c-Myc
levels have p53mutations.51 Loss of caspase-2 also results in
dysregulated p53 function in c-Myc-driven mouse lymphoma
and this is thought to be a driver of genomic instability and
accelerated tumorigenesis in this model.6,7 In contrast,
MYCN-mediated neuroblastoma essentially does not present
with p53 mutations at the time of diagnosis.44 Our findings
also demonstrate that caspase-2-deficient MYCN tumors do
not exhibit enhanced aneuploidy. This is consistent with
previous findings that genomic instability in casaspe-2-
deficient mice is positively associated with tumor onset and
progression.6,9,10
The role of caspase-2 during embryogenesis in the brain
may partly explain its novel function in neuroblastoma.
Caspase-2 was originally identified as a neuronally expressed
gene that is developmentally downregulated.52,53 Caspase-2
activation has been shown to inhibit retinoic acid-induced
neuronal differentiation,54 which suggests that high caspase-
2 expression may promote expansion of undifferentiated
neuronal cells. In addition, a role for caspase-2 in apoptosis of
sympathetic neurons is unclear. Whereas siRNA depletion of
caspase-2 can partly protect sympathetic neurons from death
induced by NGF withdrawal,55 caspase-2-deficient sympa-
thetic neurons still undergo apoptosis following factor with-
drawal.56,57 Our data have shown that caspase-2-deficient
neuroblastoma cells do not exhibit a defect in apoptosis.
Together, these studies indicate that caspase-2 is not
essential for apoptosis of neuronal cells, further providing a
context-specific function for this caspase.
In summary, this study demonstrates that caspase-2 does
not suppress tumor development in the TH-MYCN neuro-
blastoma model. In contrast, our evidence suggests that
caspase-2 expression can be a predictor of survival especially
in MYCN non-amplified human neuroblastoma. Our findings
are important in that they suggest a tissue- and/or context-
specific function for caspase-2 in different tumor models and/
or may indicate that caspase-2 may be involved in the
differential regulation of c-Myc and MYCN oncogenic signal-
ing pathways.
Materials and Methods
Mice. Casp2 / mice7,57 have been described previously and have been
backcrossed to a C57BL/6 background for at least 20 generations. 129/SvJ mice
transgenic for TH-MYCN have been previously described.19,58,59 All animals were
maintained in specific pathogen-free conditions, and all breeding and tumor
observation studies were approved by the SA Pathology/Central Northern
Adelaide Health Services Animal Ethics Committee. As the Casp2 / mice were
in a C57BL/6 genetic background, we crossed TH-MYCN hemizygous mice to
C57BL/6 wild-type mice to generate TH-MYCN hemizygous mice in a
Sv129J;C57BL/6 mixed background and monitored tumor onset and incidence
in this mixed background in comparison with the original Sv129J TH-MYCN mice.
The TH-MYCN homozygous/Casp2 / and TH-MYCN homozygous/Casp2þ /þ
were generated over two separate crosses. First, Casp2 / C57BL/6 mice
were crossed to TH-MYCN transgenic hemizygous Sv129J;C57BL/6 mice and
the resulting TH-MYCN hemizygous/Casp2þ / pups were then intercrossed
to obtain TH-MYCN homozygous/Casp2 / (TH-MYCN/Casp2 / ) and
TH-MYCN homozygous/Casp2þ /þ (TH-MYCN/Casp2þ /þ ) littermates in a
mixed Sv129/C57BL/6 background. Mice were genotyped for the presence of
MYCN transgene and loss of the Casp2 gene using primers is listed in
Supplementary Materials and Methods.
Mice were monitored for tumors by palpation and humanely killed at the onset of
pathological signs of tumor burden (hunching, poor mobility). Cause of death was
determined by autopsy. Mice that did not develop tumors after 12 months were also
humanely killed and autopsied.
Histology. Mouse tissues were collected and either snap-frozen in liquid
nitrogen and stored at  70 1C or were fixed in formalin. Fixed specimens
were embedded in paraffin, sectioned (7mm) and stained with hematoxylin
and eosin.
Real-time q-PCR. Total RNA was extracted from frozen neuroblastoma tissue
using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) and reverse-transcribed
using the High Capacity cDNA Reverse Transcription Kit (Applied Biosciences,
Foster City, CA, USA) and oligo-dT primers. Real-time qPCR was performed on a
Rotor-Gene 3000 (Corbett Research, Mortlake, NSW, Australia) using RT2 Real-
Time SYBR Green/ROX PCR Master Mix (Qiagen, Valencia, CA, USA) as per the
manufacturer’s protocol. Each gene was analyzed in two independent qPCR runs.
Gene expression was normalized to b-actin using the 2DDCt method. See
Supplementary Table 1 in Supplementary Information for primer sequences.
PCNA and TUNEL immunohistochemistry. Formalin-fixed, paraffin-
embedded thymic lymphoma sections were deparaffinized in xylene and rehydrated in
graded ethanol series. Endogenous peroxidase activity and nonspecific protein sites
were blocked with 3% H2O2/PBS and 5% fetal bovine serum/PBS-T, respectively. For
PCNA staining, tissue sections were incubated with anti-PCNA antibody (clone PC10,
Cell Signalling Technology, Danvers, MA, USA) diluted 1 : 250 in blocking solution
overnight at 4 1C. Tissue sections were incubated with anti-mouse biotinylated
secondary antibody (1 : 250 in blocking solution; GE Healthcare, Little Chalfont, UK)
and Avidin/Biotin Complex (ABC) reagent (VectaStain, Vector Laboratories,
Burlingame, CA, USA) at room temperature. For TUNEL staining, tissue sections
were treated with 20mg/ml proteinase K (Millipore, Billerica, MA, USA), and
endogenous peroxidase activity and nonspecific protein sites were blocked with 1% v/v
H2O2/PBS followed by washing in TBS (10 mM Tris, pH 8.0). Sections were pre-
incubated with terminal deoxynucleotidyl transferase (TdT) buffer (30 mM Tris pH 7.2,
140 mM sodium cacodylate, 1 mM cobalt chloride), followed by reaction buffer
containing 135 units/ml TdT enzyme (Promega, Madison, WI, USA) and 9mM
biotinylated 16-dUTP in TdT buffer at 37 1C. Negative control reactions without TdT
enzyme were included for each tissue section. Sections were treated with a saline
sodium citrate buffer (300 mM NaCl, 30 mM sodium citrate) to terminate reactions and
then were incubated with horseradish peroxidase (HRP)-conjugated streptavidin
(VectaStain). For color development, peroxidase substrate (3, 3’-diaminobenzidine)
was added, followed by counterstaining with Mayer’s hematoxylin solution (Sigma-
Aldrich, St. Louis, MO, USA). Tissue sections were then dehydrated in graded ethanol
series and coverslips were mounted using DePex mounting media. Digital images
were acquired using a NanoZoomer (Hamamatsu, Hamamatsu City, Japan).
Immunoblotting. Protein lysates were prepared from primary neuroblastoma
cells or from tumor tissue by cell lysis and/or homogenization in RIPA buffer
(25 mM Tris/HCl pH 7.4, 150 mM NaCl, 1% nonyl-phenoxylpolyethoxylethanol
(NP-40), 1% sodium deoxycholate, 0.1% sodium dodecyl sulfate (SDS) in the
presence of protease/phosphatase inhibitor cocktail (Thermo Fisher Scientific,
Waltham, MA, USA). Homogenates were further treated by three freeze/thaw
cycles in liquid nitrogen, clarified by centrifugation at 16 000 g for 15 min and
protein concentration determined by the BCA quantification (Pierce Biotechnology
Inc, Thermo Fisher Scientific). For immunoblot analysis, 50 mg of lysates were
resolved on 12% SDS-PAGE and transferred onto PVDF membrane and probed
for the specified antibody for 2 h at room temperature or overnight at 4 1C.
Secondary antibodies, conjugated with HRP (GE Healthcare), alkaline phospha-
tase (AP, Millipore) or Cy5 (GE Healthcare), were incubated at room temperature
for 2 h. Proteins were visualized using ECF or ECL (Amersham, Sunnyvale, CA,
USA). The following primary antibodies were used: N-MYC-(2) and p21 (F5)
(Santa Cruz Biotechnology Inc, Santa Cruz, CA, USA); Ras (27H5), p44/42 MAPK
(Erk1/2) (137F5), phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (D13.14.4E),
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Akt (pan) (C67E7), Phospho-Akt (Ser473) (D9E) (Cell Signalling Technology),
caspase-2 (clone 11B4), b-actin (Sigma).
Statistical analysis of data. Graph Pad Prism software, version 5 (Graph
Pad Inc, CA, USA) was used for all statistical analysis. Log-rank and Gehan–
Breslow–Wilcoxon tests with Kaplan–Meier analysis were used for comparison of
mouse survival. Student’s t-test or w2 tests were used for all other analysis unless
otherwise stated. Data are expressed as mean±S.E.M. Po0.05 was considered
significant.
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